$82.4 Million is the total value of NEXTHERA CAPITAL LP's 24 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BOLD | Sell | Audentes Therapeutics Inc | $9,779,000 | -40.0% | 250,620 | -67.2% | 11.87% | +76.7% |
| HRTX | Sell | Heron Therapeutics Inc | $9,498,000 | -55.3% | 388,623 | -52.6% | 11.53% | +31.6% |
| INSM | Sell | Insmed Inc | $8,264,000 | -24.9% | 284,263 | -66.1% | 10.03% | +121.0% |
| IMMU | Sell | Immunomedics Inc | $6,430,000 | -49.6% | 334,724 | -62.6% | 7.80% | +48.3% |
| BHC | Sell | Bausch Health Cos Inc | $5,080,000 | -58.6% | 205,660 | -69.1% | 6.16% | +21.8% |
| URGN | New | UroGen Pharma Ltd | $4,898,000 | – | 132,589 | +100.0% | 5.94% | – |
| GBT | Sell | Global Blood Therapeutics Inc | $4,610,000 | -49.3% | 87,099 | -60.7% | 5.60% | +49.2% |
| STML | Sell | Stemline Therapeutics Inc | $4,183,000 | -38.1% | 325,526 | -54.3% | 5.08% | +82.2% |
| NVS | Sell | Novartis AGsponsored adr | $3,834,000 | -85.9% | 45,329 | -85.7% | 4.65% | -58.4% |
| AMRN | New | Amarin Corp PLCspons adr new | $3,087,000 | – | 148,695 | +100.0% | 3.75% | – |
| CBAY | Sell | Cymabay Therapeutics Inc | $2,792,000 | -50.4% | 210,257 | -70.6% | 3.39% | +46.2% |
| SRPT | New | Sarepta Therapeutics Inc | $2,535,000 | – | 21,270 | +100.0% | 3.08% | – |
| QURE | New | uniQure NV | $2,314,000 | – | 38,800 | +100.0% | 2.81% | – |
| EXEL | Sell | Exelixis Inc | $2,150,000 | -64.5% | 90,356 | -70.6% | 2.61% | +4.6% |
| NBIX | New | Neurocrine Biosciences Inc | $2,118,000 | – | 24,040 | +100.0% | 2.57% | – |
| ACOR | New | Acorda Therapeutics Inc | $2,057,000 | – | 154,806 | +100.0% | 2.50% | – |
| AGN | New | Allergan PLC | $2,006,000 | – | 13,700 | +100.0% | 2.43% | – |
| ICPT | New | Intercept Pharmaceuticals Inc | $1,337,000 | – | 11,952 | +100.0% | 1.62% | – |
| KNSA | New | Kiniksa Pharmaceuticals Ltd | $1,223,000 | – | 67,692 | +100.0% | 1.48% | – |
| CHMA | Sell | Chiasma Inc | $1,061,000 | -68.0% | 203,948 | -80.9% | 1.29% | -5.8% |
| DCPH | Sell | Deciphera Pharmaceuticals Inc | $995,000 | -61.1% | 42,865 | -64.8% | 1.21% | +14.4% |
| SAGE | New | Sage Therapeutics Inc | $986,000 | – | 6,200 | +100.0% | 1.20% | – |
| BMRN | New | BioMarin Pharmaceutical Inc | $733,000 | – | 8,250 | +100.0% | 0.89% | – |
| MDGL | New | Madrigal Pharmaceuticals Inc | $432,000 | – | 3,452 | +100.0% | 0.52% | – |
| VCNX | Exit | Vaccinex Inc | $0 | – | -17,047 | -100.0% | -0.03% | – |
| MDWD | Exit | MediWound Ltd | $0 | – | -104,546 | -100.0% | -0.18% | – |
| OSMT | Exit | Osmotica Pharmaceuticals PLC | $0 | – | -120,620 | -100.0% | -0.38% | – |
| ATNX | Exit | Athenex Inc | $0 | – | -123,305 | -100.0% | -0.64% | – |
| ZSAN | Exit | Zosano Pharma Corp | $0 | – | -798,719 | -100.0% | -0.70% | – |
| STRO | Exit | Sutro Biopharma Inc | $0 | – | -249,496 | -100.0% | -0.93% | – |
| CBIO | Exit | Catalyst Biosciences Inc | $0 | – | -376,010 | -100.0% | -1.22% | – |
| HZNP | Exit | Horizon Pharma Plc | $0 | – | -396,198 | -100.0% | -3.19% | – |
| TEVA | Exit | Teva Pharmaceutical Industriescall | $0 | – | -1,683,500 | -100.0% | -10.70% | – |
| BMRN | Exit | BioMarin Pharmaceutical Inccall | $0 | – | -341,400 | -100.0% | -11.98% | – |
| XBI | Exit | SPDR S&P Biotech ETFput | $0 | – | -499,200 | -100.0% | -14.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.